Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment.
Journal of psychopharmacology (Oxford, England) 2025 Luis Gutiérrez-Rojas, Julia Vendrell-Serres, Josep Antoni Ramos‐quiroga et al. 8 citations
Treatment-resistant depression (TRD) is defined as the failure of at least two antidepressants in adequate doses and timing during a major depressive episode. Esketamine intranasal (ESK-IN) has been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of TRD in combination with other antidepressants. To assess the effectiveness and tolerability of a...